<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55237">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01779232</url>
  </required_header>
  <id_info>
    <org_study_id>CR-09-2013</org_study_id>
    <nct_id>NCT01779232</nct_id>
  </id_info>
  <brief_title>Danazol Treatment in Endometriosis Women Before IVF</brief_title>
  <official_title>Treatment With Danazol Before Controlled Ovarian Hyperstimulation in Women With Endometriosis Undergoing IVF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Endocrinology and Reproductive Medicine, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for Endocrinology and Reproductive Medicine, Italy</source>
  <oversight_info>
    <authority>Italy: National Monitoring Centre for Clinical Trials - Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether pre-treatment with danazol for at least 4
      months before controlled ovarian hyperstimulation for IVF cycles improves pregnancy rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endometriosis is a chronic benign disease defined by the presence of endometrial tissue
      outside the uterine cavity, affecting women in their reproductive age. This disease is
      clinically characterized by infertility pelvic pain and the presence of ovarian cysts,
      endometriomas, and affects the about 10% of women. Women with endometriosis when undergo IVF
      show lower pregnancy rate than general population, and a reduced ovarian reserve, due to the
      diseases and often to ovarian surgery. The aim of this study is to evaluate if a
      pre-treatment with danazol, an anti-estrogenic agent, may improve the otcome of IVF cycles
      in these women
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>pregnancy rate</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>number of ongoing pregnancy for the number of IVF cycles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>implantation rate</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>number of embryos implanted for the total number of embryos transferred</description>
  </secondary_outcome>
  <other_outcome>
    <measure>number of mature oocyte collected</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>number of mature oocyte collected for patient undergoing IVF</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Endometriosis</condition>
  <condition>Ovarian Cysts</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients treated with placebo for at least 4 months before IVF attempt</description>
  </arm_group>
  <arm_group>
    <arm_group_label>danazol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients treated with danazol (100mg/day)for at least 4 months before IVF attempt</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danazol</intervention_name>
    <description>100 mg day for 4 monthh in women with diagnosed endometriosis before IVF</description>
    <arm_group_label>danazol</arm_group_label>
    <other_name>Danatrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>administered daily like the active comparator</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Clinical diagnosis of endometriosis previous laparoscopic surgery for ovarian
        endometriotic cysts infertility

        Exclusion Criteria:

        - age more than 40 years systemic disease antimulleran hormone (AMH)&lt;1 and FSH&gt;20
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Sbracia, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre for Endocrinology and Reproductive Medicine, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marco Sbracia, MD</last_name>
    <phone>+393479037433</phone>
    <email>marcandrea@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniela Marconi, MD</last_name>
    <phone>+39065810461</phone>
    <email>quelidebercia@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CERM</name>
      <address>
        <city>Rome</city>
        <zip>00153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Sbracia, MD</last_name>
      <phone>+393479037433</phone>
      <email>marcandrea@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Marconi, MD</last_name>
      <phone>+39065810461</phone>
      <email>quelidebercia@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Fabio Scarpellini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 2, 2013</lastchanged_date>
  <firstreceived_date>January 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Endocrinology and Reproductive Medicine, Italy</investigator_affiliation>
    <investigator_full_name>Fabio Scarpellini</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>endometriosis</keyword>
  <keyword>ivf</keyword>
  <keyword>ovarian reserve</keyword>
  <keyword>danazol</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Ovarian Cysts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Danazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
